WO2012074237A2 - Liquid medicine composition including dorzolamide and brimonidine for ophthalmology - Google Patents

Abstract

The present invention provides a liquid medicine composition including as active ingredients dorzolamide or a salt thereof, timolol or a salt thereof, and brimonidine or a salt thereof, for ophthalmology, which is stable and non-irritant. More particularly, the present invention provides a liquid medicine composition for ophthalmology comprising: 1-3 w/v% of dorzolamide or the salt thereof; 0.1-1 w/v% of timolol or the salt thereof; 0.1-0.5 w/v% of brimonidine or the salt thereof; 1.0-1.5 w/v% of polyvinylpyrrolidone; 0.2-0.8 w/v% of sodium chloride; 0.3-0.6 w/v% of a buffering agent; a preservative; a pH controlling agent; and water.

Description

Ophthalmic liquid composition comprising dorzolamide, timolol and brimonidine

The present invention relates to a stable and non-irritating ophthalmic liquid composition comprising dorzolamide or a salt thereof, timolol or a salt thereof, and brimonidine or a salt thereof as an active ingredient.

Dorzolamide is an aromatic sulfonamide derivative known as carbonic anhydrase inhibitors useful for the treatment of elevated intraocular pressure and is a drug used to treat glaucoma in the form of acid addition salts such as hydrochloride ( U.S. Patent 4,797,413).

Brimonidine has the chemical name 5-bromo-6- (2-imidazolidinylideneamino) quinoxaline and is an alpha adrenergic agent used to provide neuroprotection to the eye. In the form of glaucoma (US Pat. Nos. 3,890,319, 5,856,329, 6,194,415, 6,248,741, etc.).

Timolol has the chemical name (S)-(-)-1- (tert-butylamino) -3-[(4-morpholino-1,2,5-thiadiazol-3-yl) oxy] -2- Propanol, known as a beta adrenergic receptor blocker, is used to treat glaucoma in the form of maleate (US Pat. Nos. 4,195,085 and 4,861,760, etc.).

US Pat. No. 6,156,785 discloses a method for increasing optic nerve and retinal oxygen tension by administering to the eye a composition comprising a carbonic anhydrase inhibitor such as dorzolamide and a beta adrenergic receptor blocker such as timolol. Has been disclosed. In addition, US Pat. No. 6,313,155 discloses a method for increasing retinal blood flow by simultaneously administering a carbonic anhydrase inhibitor such as dorzolamide and a beta adrenergic receptor blocker such as timolol. Preparations for the treatment of glaucoma D'Isola in 1998 contained the mid 2.0% and timolol 0.5% (product name: kosop ^TM (Cosopt ^TM), MSD) is approved by the FDA are currently used in clinical practice. Kohsin ^TM (Korea MSD) is a formulation obtained by dissolving hydroxyethyl cellulose, mannitol, sodium citrate, sodium hydroxide, and benzalkonium chloride in sterile water together with dorzolamide hydrochloride and timolol maleate.

WO2003 / 088973 (Korean Patent Registration No. 10-0723189) discloses an ophthalmic composition useful for the treatment of glaucoma or ocular hypertension, comprising 0.2% by weight of brimonidine and 0.5% by weight of thymolol. It was initiated. The composition has received approval from the US Food and Drug Administration (FDA) to (between Combigan ^TM, Allergan) ^TM 2007 between the duo is currently being used in clinical trials.

Kosop the ^TM and the combination between the ^TM is being used for the purpose of the treatment of glaucoma patients, in the case of patients with severe cases of glaucoma has a break of 5 minutes is administered twice once. Therefore, it is easy for the patient to forget the eye drops after 5 minutes, which is a disadvantage of low compliance with the medication. Recently, US Patent Publication No. 2009/0069345 discloses a composition for treating complex glaucoma of dorzolamide, timolol, and brimonidine, which can be administered once daily. The composition according to U.S. Patent Publication No. 2009/0069345 discloses polyoxyl 40 stearate as a solubilizer and tonicating agent sodium chloride in addition to the active ingredients (i.e. dorzolamide, timolol, and brimonidine). And mannitol. In particular, it is disclosed that mannitol must be used essentially to reduce irritation, and solubilizers such as polyoxyl 40 stearate are essential to achieve chemical stability.

However, it is desirable from the viewpoint of safety that the additives contained in the formulation are minimized as much as possible due to the nature of the eye drop formulation. Therefore, the development of ophthalmic formulations with good stability and hypoallergenicity, while avoiding the use of surfactants such as polyoxyl 40 stearate and the use of sugars such as mannitol, which can provide good conditions for microbial propagation, is avoided. Required.

The present invention relates to a three-component ophthalmic preparation useful for treating glaucoma, ie, a three-component ophthalmic preparation comprising dorzolamide or a salt thereof, timolol or a salt thereof, and brimonidine or a salt thereof, which is stable and minimizes additives. It also provides a non-irritating ophthalmic liquid composition.

That is, an object of the present invention is to provide a stable and non-irritating ophthalmic liquid composition comprising dorzolamide or a salt thereof, timolol or a salt thereof, and brimonidine or a salt thereof.

According to one aspect of the present invention, Dorzolamide or a salt thereof 1-3 w / v%; Timolol or its salt 0.1-1 w / v%; Brimonidine or its salt 0.1-0.5 w / v%; Polyvinylpyrrolidone 1.0 to 1.5 w / v%; Sodium chloride 0.2-0.8 w / v%; Buffer 0.3 to 0.6 w / v%; Preservatives; pH regulators; And an ophthalmic liquid composition composed of water.

In one embodiment, 1 to 3 w / v% of dorzolamide hydrochloride; Timolol maleate 0.1-1 w / v%; Brimonidine stannate 0.1-0.5 w / v%; Polyvinylpyrrolidone 1.0 to 1.5 w / v%; Sodium chloride 0.2-0.8 w / v%; Buffer 0.3 to 0.6 w / v%; Preservatives; pH regulators; And an ophthalmic liquid composition composed of water.

In another embodiment, 2.23 w / v% dorzolamide hydrochloride; Timolol maleate 0.68 w / v%; Brimonidine stannate 0.2 w / v%; Polyvinylpyrrolidone 1.14 w / v%; Sodium chloride 0.31 w / v%; 0.46 w / v% of a mixture of citric acid and sodium citrate; Benzalkonium chloride 0.005 w / v%; pH regulators; And an ophthalmic liquid composition composed of water.

Dozolamide or a salt thereof, timolol or a salt thereof, and brimonidine or a salt thereof, using a specific thickener, i.e., polyvinylpyrrolidone, and as other additives sodium chloride, buffers, preservatives, pH adjusting agents When prepared in the form of a three-component ophthalmic solution composition by dissolving in water, it is possible to achieve excellent stability without using a surfactant such as polyoxyl 40 stearate, and also to provide good conditions for the growth of microorganisms mannitol It has been found that irritation can be minimized without the use of sugars. In particular, the ophthalmic liquid composition according to the present invention is minimized in the kind of additives, and thus is made of surfactant-free and glucose-free (particularly mannitol-free). Since the preparation of an ophthalmic liquid formulation is possible, it can be very usefully used as an eye drop formulation which is directly administered to the eye.

1 is a result of measuring the content (% by weight) of cis-dorzolamide hydrochloride, a known soft material of dorzolamide hydrochloride, while storing for 3 months at 40 ° C. and 75% relative humidity.

Figure 2 is a result of measuring the change in the content (wt%) of the unknown flexible material derived from dorzolamide hydrochloride while stored for 3 months at 40 ℃ and 75% relative humidity conditions.

Figure 3 is a result of measuring the change in the content (wt%) of the total analog derived from dorzolamide hydrochloride while stored for 3 months at 40 ℃ and 75% relative humidity conditions.

Figure 4 is a result of measuring the change in the content (% by weight) of the unknown flexible material derived from timolol maleate while stored for 3 months at 40 ℃ and 75% relative humidity conditions.

Figure 5 is a result of measuring the change in the content (% by weight) of the total analog derived from timolol maleate while stored for 3 months at 40 ℃ and 75% relative humidity conditions.

Figure 6 is a result of measuring the change in the content (wt%) of the unknown flexible material derived from brimonidine stannate, while stored for 3 months at 40 ℃ and 75% relative humidity conditions.

Figure 7 is a result of measuring the change in the content (wt%) of the total analog derived from brimonidine stannate while stored for 3 months at 40 ℃ and 75% relative humidity conditions.

The present invention provides 1 to 3 w / v% of Dorzolamide or a salt thereof; Timolol or its salt 0.1-1 w / v%; Brimonidine or its salt 0.1-0.5 w / v%; Polyvinylpyrrolidone 1.0 to 1.5 w / v%; Sodium chloride 0.2-0.8 w / v%; Buffer 0.3 to 0.6 w / v%; Preservatives; pH regulators; And water for ophthalmic liquid compositions.

The composition of the present invention comprises dorzolamide or a salt thereof, timolol or a salt thereof, brimonidine or a salt thereof as an active ingredient. Dorzolamide hydrochloride may preferably be used as the dozolamide or a salt thereof, and may be contained at a concentration of 1 to 3 w / v%, more preferably about 2.23 w / v%. Timolol maleate may be preferably used as the timolol or a salt thereof, and may be contained at a concentration of 0.1 to 1 w / v%, more preferably about 0.68 w / v%. Brimonidine tartrate may be preferably used as brimonidine or a salt thereof, and may be contained at a concentration of 0.1 to 0.5 w / v%, more preferably about 0.2 w / v%.

The ophthalmic liquid composition according to the present invention contains a minimized additive. That is, the composition according to the present invention comprises polyvinylpyrrolidone as a thickener, sodium chloride as a tonicity agent, a buffer, a preservative, a pH adjuster.

The polyvinylpyrrolidone may be contained in an amount necessary to maintain the viscosity of the resulting ophthalmic liquid composition in the range of 2.5 to 3.5 cps, for example 1.0 to 1.5 w / v%, more preferably about 1.14 w It may be contained at a concentration of / v%.

The sodium chloride may be contained in an amount necessary to maintain the osmotic pressure of the resulting ophthalmic liquid composition in the range of 250 to 350 mOsm (preferably 280 to 300 mOsm), for example, 0.2 to 0.8 w / v%, more preferably Preferably at a concentration of about 0.31 w / v%.

The buffer may use a combination of various acids and salts thereof, for example a combination of citric acid and sodium citrate. The concentration of the buffer may range from 0.3 to 0.6 w / v%, but is not limited thereto. For example, the ophthalmic liquid composition of the present invention may contain about 0.013 w / v% citric acid and about 0.45 w / v% sodium citrate.

The preservative may be a preservative (for example benzalkonium chloride) commonly used in ophthalmic preparations, the content is not particularly limited, but 0.002 to 0.05 w / v%, preferably 0.005 w / v It may contain%. In addition, the pH adjusting agent may be added to adjust the pH of the resulting ophthalmic liquid composition to an appropriate range, for example about pH 5.2, it can be usually used hydrochloric acid or sodium hydroxide. The pH adjusting agent may be used in an amount necessary to obtain an appropriate range of pH, and is not particularly limited.

In the composition of the present invention, the water used as the aqueous medium may be sterile purified water, water for injection, and the like suitable for the preparation of an ophthalmic preparation. The ophthalmic liquid composition of the present invention can be obtained by dissolving the active ingredient and the additive in water. Ophthalmic liquid compositions according to the invention can be used in the form of conventional eye drops (eye drop).

In one embodiment of the invention, 1 to 3 w / v% dorzolamide hydrochloride; Timolol maleate 0.1-1 w / v%; Brimonidine stannate 0.1-0.5 w / v%; Polyvinylpyrrolidone 1.0 to 1.5 w / v%; Sodium chloride 0.2-0.8 w / v%; Buffer 0.3 to 0.6 w / v%; Preservatives; pH regulators; And an ophthalmic liquid composition composed of water.

In another embodiment of the invention, 2.23 w / v% dorzolamide hydrochloride; Timolol maleate 0.68 w / v%; Brimonidine stannate 0.2 w / v%; Polyvinylpyrrolidone 1.14 w / v%; Sodium chloride 0.31 w / v%; 0.46 w / v% of a mixture of citric acid and sodium citrate; Benzalkonium chloride 0.005 w / v%; pH regulators; And an ophthalmic liquid composition composed of water.

Hereinafter, the present invention will be described in more detail with reference to Examples. However, these examples are for illustrating the present invention, and the scope of the present invention is not limited to these examples.

Example 1 Eye Drop Solution

11.4 g of polyvinylpyrrolidone was added to 400 ml of sterile purified water, and the mixture was dissolved by heating to 80 to 95 ° C. After the solution was cooled to a temperature of 45 to 50 ° C., 22.26 g of dorzolamide hydrochloride, 6.83 g of timolol maleate, 0.05 g of benzalkonium chloride, 0.13 g of citric acid, 4.5 g of sodium citrate hydrate, and 3.14 g of sodium chloride were added thereto, followed by stirring. It was. The solution was cooled to room temperature and dissolved by adding 2 g of brimonidine stannate and stirring. After adjusting the pH to 5.2 using hydrochloric acid to the obtained solution, sterile purified water was added to adjust the final volume to 1,000 ml to prepare an eye drop solution.

Comparative Example 1. Eye Drop

4.75 g of hydroxyethyl cellulose was added to 600 ml of sterile purified water, and the mixture was dissolved by heating to 80 to 95 ° C. After the solution was cooled to a temperature of 45 to 50 ° C., 22.26 g of dorzolamide hydrochloride, 6.83 g of timolol maleate, 0.05 g of benzalkonium chloride, 0.13 g of citric acid, 2.94 g of sodium citrate hydrate, and 16.0 g of mannitol were added thereto, followed by stirring. It was. The solution was cooled to room temperature and dissolved by adding 2 g of brimonidine stannate and stirring. After adjusting the pH to 5.2 using sodium hydroxide to the obtained solution, sterile purified water was added to adjust the final volume to 1,000 ml to prepare an eye drop solution.

Test Example 1 Flexible Material Measurement Test

(1) Test of Flexibility of Dorzolamide Hydrochloride

While the eye drops prepared in Example 1 and Comparative Example 1 were stored at 40 ° C. and 75% relative humidity for 3 months, the change in the flexible substance of dorzolamide hydrochloride was measured by high performance liquid chromatography (HPLC). It was. HPLC operating conditions are as follows.

<Conductor Test Conditions for Dorzolamide Hydrochloride (HPLC)>

Column: Luna C ₈ column (25cmx4.6mm, 5㎛)

-Column temperature: 30 ℃

-Detector: ultraviolet absorption photometer (wavelength: 253nm)

-Mobile phase A: 2 mL of phosphoric acid was added to a 1000 mL volumetric flask, and prepared by adjusting the mark with water, followed by filtration.

Mobile phase B: Acetonitrile was used by filtration.

Solution A: Mobile phase A and mobile phase B were mixed and used in a ratio of 95: 5 (volume ratio).

Flow rate: 1.2 mL / min

Run time: 30 minutes

Concentration gradient: Use of mobile phase concentration gradient of Table 1 below

Table 1

Minutes	Mobile phase A (%)	Mobile phase B (%)
0	95	5
15.0	95	5
15.1	5	95
20.0	5	95
20.1	95	5
30.0	95	5

<Test Results>

The change in the flexible material measured under the above conditions is as shown in FIGS. 1 is a result of measuring the content (wt%) of cis-dorzolamide hydrochloride, a known flexible material of dorzolamide hydrochloride, and FIG. 2 is a result of measuring a change in the content (wt%) of an unknown flexible material. 3 is the result of measuring the change in content (wt%) of the total lead. As can be seen from the results of FIGS. 1 to 3, the ophthalmic solution composition of the present invention has excellent stability due to less generation of cis-dorzolamide hydrochloride, an unknown flexible material, and a total soft substance compared to the formulation of Comparative Example 1. Indicated.

(2) Testing of Lead Material of Timolol Maleate

While the eye drops prepared in Example 1 and Comparative Example 1 were stored at 40 ° C. and 75% relative humidity for 3 months, the change in the flexible substance of dorzolamide hydrochloride was measured by high performance liquid chromatography (HPLC). It was. HPLC operating conditions are as follows.

<Condition Test Conditions for Timolol Maleate (HPLC)>

Column: Capcellpak C ₁₈ column (25cmx4.6mm, 5㎛)

-Column temperature: 40 ℃

-Detector: ultraviolet absorption photometer (wavelength: 295nm)

Solution A: 24.9 g of sodium dihydrogen phosphate dihydrate (NaH ₂ PO ₄ · 2H ₂ O) was taken into a 2000 mL volumetric flask and dissolved with 1900 mL of water. The pH was adjusted to 2.8 with phosphoric acid, followed by water mark, followed by filtration.

Mobile phase: Solution A and methanol were mixed and filtered at a ratio of 1200: 800 (volume ratio).

Flow rate: 1.0 mL / min

Run time: 15 minutes

<Test Results>

The change in the flexible material measured under the above conditions is as shown in FIGS. 4 and 5. Figure 4 is the result of measuring the content (wt%) change of the unknown flexible material, Figure 5 is the result of measuring the content (wt%) change of the total flexible material. As can be seen from the results of FIG. 4 and FIG. 5, the ophthalmic liquid composition of the present invention exhibited excellent stability due to less generation of an unknown flexible material and a total flexible material than the formulation of Comparative Example 1.

(3) Determination of Lead Material of Brimonidine Tartrate

While the eye drops prepared in Example 1 and Comparative Example 1 were stored at 40 ° C. and 75% relative humidity for 3 months, the change in the flexible substance of dorzolamide hydrochloride was measured by high performance liquid chromatography (HPLC). It was. HPLC operating conditions are as follows.

<Condition Test Conditions for Brimonidine Tartrate (HPLC)>

Column: LiChrospher 60 RP select B (5 μm, 4 × 250 mm)

-Column temperature: 30 ℃

-Detector: ultraviolet absorbance photometer (wavelength: 248nm)

-Mobile phase A: 7.8 g of NaH ₂ PO ₄ · 2H ₂ O and 5.0 g of phosphoric acid were diluted with water to 1 L, and the pH was adjusted to 2.0-2.2 with phosphoric acid or NaH ₂ PO ₄ · 2H ₂ O to prepare a buffer solution. It was then used by filtration.

Mobile phase B: Phosphoric acid was added to acetonitrile to make 0.05% (V / V), followed by filtration.

Flow rate: 0.8 mL / min

Run time: 50 minutes

Concentration gradient: Use of mobile phase concentration gradient of Table 2 below

TABLE 2

Time (min)	Mobile phase A (%)	Mobile phase B (%)
0	95	5
30	73	27
35	73	27
40	95	5
50	95	5

<Test Results>

The change in the flexible material measured under the above conditions is the same as in FIGS. 6 and 7. Figure 6 is the result of measuring the content (wt%) change of the unknown flexible material, Figure 7 is the result of measuring the content (wt%) change of the total flexible material. As can be seen from the results of FIG. 6 and FIG. 7, the ophthalmic liquid composition of the present invention exhibited excellent stability due to less production of unknown flexible materials and total flexible materials than the formulation of Comparative Example 1.

Test Example 2 Long-term preservation test and accelerated test

(1) long-term preservation test

The long-term preservation test was performed while the eye drop prepared in Example 1 was stored for 12 months under conditions of 15-25 ° C. and 60% relative humidity. HPLC analysis conditions are the same as in Test Example 1, the results are shown in Table 3 below.

TABLE 3

		standard	Early	3 months	6 months	9 months	12 months
Constellation		Light yellow clear water soluble eye drops	Left	Left	Left	Left	Left
pH		4.2 to 6.2	5.21	5.24	5.20	5.25	5.31
Osmotic pressure		250 to 350 (mOsm)	291	290	292	295	296
Dorzolamide Hydrochloride	Leading substance	Cisdorzolamide: 2.0% or less	Not detected	0.11%	0.25%	0.28%	0.30%
		Maximum unknown flexible material: 0.5% or less	Not detected	0.02%	0.03%	0.03%	0.03%
		Total Lead: 2.5% or less	Not detected	0.13%	0.28%	0.31%	0.33%
	content	90.0 to 110.0% of display amount	100.0%	99,9%	99,7%	100.1%	100.2%
Timolol maleate	Leading substance	Maximum unknown flexible material: 0.5% or less	Not detected	Not detected	Not detected	0.01%	0.01%
		Total Lead: 1.0% or less	Not detected	Not detected	Not detected	0.02%	0.02%
	content	90.0 to 110.0% of display amount	100.1%	100.2%	100.0%	100.3%	100.0%
Brimonidine Tartrate	Leading substance	Maximum unknown: 0.3% or less	Not detected	0.01%	0.02%	0.03%	0.04%
		Total Lead: Less than 2.4%	Not detected	0.09%	0.14%	0.23%	0.25%
	content	90.0 to 110.0% of display amount	100.0%	99.9%	99.8%	100.4%	100.1%

As can be seen from the results in Table 3, it can be seen that the composition of the present invention has excellent physical and chemical stability for 12 months.

(2) accelerated test

An accelerated test was performed while the eye drop prepared in Example 1 was stored for 6 months at 40 ° C. and 75% relative humidity. HPLC analysis conditions are the same as in Test Example 1, the results are shown in Table 4 below.

Table 4

		standard	Early	1 month	3 months	6 months
Constellation		Light yellow clear water soluble eye drops	Left	Left	Left	Left
pH		4.2 to 6.2	5.21	5.22	5.25	5.33
Osmotic pressure		250 to 350 (mOsm)	291	292	292	295
Dorzolamide Hydrochloride	Leading substance	Cisdorzolamide: 2.0% or less	Not detected	0.12%	0.27%	0.34%
		Maximum unknown flexible material: 0.5% or less	Not detected	0.02%	0.04%	0.05%
		Total Lead: 2.5% or less	Not detected	0.14%	0.31%	0.39%
	content	90.0 to 110.0% of display amount	100.0%	100.0%	100.2%	99.9%
Timolol maleate	Leading substance	Maximum unknown flexible material: 0.5% or less	Not detected	Not detected	0.01%	0.01%
		Total Lead: 1.0% or less	Not detected	Not detected	0.03%	0.03%
	content	90.0 to 110.0% of display amount	100.1%	99.9%	99.7%	99.9%
Brimonidine Tartrate	Leading substance	Maximum unknown flexible material: Less than 0.3%	Not detected	0.05%	0.11%	0.17%
		Total Lead: Less than 2.4%	Not detected	0.20%	0.57%	0.77%
	content	90.0 to 110.0% of display amount	100.0%	100.1%	99.9%	100.5%

As can be seen in the results of Table 4, it can be seen that the composition of the present invention has excellent physical and chemical stability for 6 months.

Test Example 3 Ocular Membrane Stimulation Test

An ophthalmic mucosa stimulation test was performed on the eye drops obtained in Example 1. This test was carried out in accordance with the 10-BL-301 protocol (internal control number), and the preparation and testing of this protocol was carried out in the toxicity standard of medicines (2009-116, KFDA, August 4, 2009). The study was conducted in accordance with the Nonclinical Study Controls (2009-183, KFDA, December 22, 2009) and the OECD Principles of Good Laboratory Practice (1997). The ophthalmic solution obtained in Example 1 was administered to the New Zealand White rabbit's eye mucosa at a dose of 0.1 mL / head, and symptoms were observed for 7 days.

As a result of the ocular mucosal irritation test, (1) no general symptoms or deaths related to the application of the test substance were observed during the test period, (2) no weight change related to the application of the test substance was observed during the test period, and (3) As a result of observation of eye reaction after application of test substance, no change was observed in both eyes group and micro eye group. (4) As a result of observation of eye reaction after application of test substance, The Index of Acute Ocular Irritation (IAOI) During the entire observation period, both the eye and micro-eye groups were evaluated as non-irritating to 0.

Therefore, the ophthalmic liquid composition prepared according to the present invention was found to have no irritation and excellent eye drop when applied to the eye mucosa.

Claims (3)

1. Dozolamide or salts thereof in the range of 1 to 3 w / v%; Timolol or its salt 0.1-1 w / v%; Brimonidine or its salt 0.1-0.5 w / v%; Polyvinylpyrrolidone 1.0 to 1.5 w / v%; Sodium chloride 0.2-0.8 w / v%; Buffer 0.3 to 0.6 w / v%; Preservatives; pH regulators; And water, an ophthalmic liquid composition.
2. The method according to claim 1, wherein the dozolamide hydrochloride 1 to 3 w / v%; Timolol maleate 0.1-1 w / v%; Brimonidine stannate 0.1-0.5 w / v%; Polyvinylpyrrolidone 1.0 to 1.5 w / v%; Sodium chloride 0.2-0.8 w / v%; Buffer 0.3 to 0.6 w / v%; Preservatives; pH regulators; And water, an ophthalmic liquid composition.
3. The method according to claim 2, further comprising: 2.23 w / v% dorzolamide hydrochloride; Timolol maleate 0.68 w / v%; Brimonidine stannate 0.2 w / v%; Polyvinylpyrrolidone 1.14 w / v%; Sodium chloride 0.31 w / v%; 0.46 w / v% of a mixture of citric acid and sodium citrate; Benzalkonium chloride 0.005 w / v%; pH regulators; And water, an ophthalmic liquid composition.

Images